A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)

PHASE4CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 4, 2021

Primary Completion Date

October 9, 2025

Study Completion Date

October 9, 2025

Conditions
Muscular Atrophy, Spinal
Interventions
DRUG

Nusinersen

Administered as specified in the treatment arm.

Trial Locations (15)

19104

Children's Hospital Philadelphia - Neurology, Philadelphia

20133

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan

20246

Universitaetsklinikum Hamburg-Eppendorf, Hamburg

23510

Children's Hospital of The King's Daughters, Norfolk

28046

Hospital Universitario La paz, Madrid

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

72202

Arkansas Children's Hospital Research Institute, Little Rock

80045

Children's Hospital Colorado, Aurora

84112

University of Utah, Salt Lake City

94304

Stanford Neuromuscular Research, Palo Alto

97239

Oregon Health and Science University (OHSU), Portland

4920235

Schneider Children's Medical Center, Petah Tikva

02114

Massachusetts General Hospital, Boston

00168

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

08950

Hospital Sant Joan de Déu, Esplugues Del Llobregat

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY